Floatz logo

Decoy20

UC (Urothelial Cancer)

Indaptus Therapeutics, IncPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

166 Active assets in the UC (Urothelial Cancer) cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Beijing Biotech
Phase 3BB
Durvalumab
Alliance for Clinical Trials in Oncology
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BB
Pembrolizumab
Sutro Biopharma, Inc.
Phase 3BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Vasgene Therapeutics, Inc
Phase 2/3BB

View all 50 →

Same molecule, other indications

Decoy20 is also rated in:

MSI-H CancerDormant
CC
Indicative ·
47 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
45 / 100
View asset →
hepatocellular carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →